The Toronto Stock Exchange s TSX rises 0.19 percent to 19,564.12 Leading the index were Aurora Cannabis Inc , up 6.0%, Toromont Industries Ltd, up 5.7%, and Canopy Growth Corp, higher by 5.2%. Lagging shares were Trillium Therapeutics Inc, down 9.5%, AcuityAds Holdings Inc, down 5.6%, and Nexgen Energy Ltd, lower by 5.6%. On the TSX 106 issues rose and 120 fell as a 0.9-to-1 ratio favored decliners. There were 18 new highs and no new lows, with total volume of 232.2 million shares. The most heavily traded shares by volume were Enbridge Inc, Suncor Energy Inc and Manulife Financial Corp. The TSX s energy group fell 1.04 points, or 0.8%, while the financials sector climbed 0.44 points, or 0.1%.
Share this article
Share this article
NEW YORK, May 25, 2021 /PRNewswire/ The cancer therapeutics market is one of the largest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in the United States in 2020 alone. However, the oncology and cancer drug market is expected to grow largely due to the surge in cancer research, the rise in the geriatric population worldwide, as well as the increase in collaboration between pharmaceutical companies. Moreover, the high market growth potential in developing nations, a rise in the number of pipeline products, and an upsurge in demand for personalized medicines are expected to create new opportunities for market players. And, according to data published by Market Industry Reports, the cancer therapeutics market was estimated to be valued at over USD 140 Billion in 2019 and is anticipated to grow at a CAGR of ~7.7% from 2019 to 2030. Sunshine Biopharma Inc
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., May 20, 2021 /PRNewswire/ Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is ex
TSX falls 0.1% to 19,290.98
05/06/2021 | 05:27pm EDT
Send by mail :
Message : The Toronto Stock Exchange s TSX falls 0.10 percent to 19,290.98 Leading the index were Endeavour Silver Corp , up 10.0%, ARC Resources Ltd, up 8.5%, and SSR Mining Inc, higher by 8.1%. Lagging shares were Lithium Americas Corp, down 9.0%, Trillium Therapeutics Inc, down 7.8%, and AcuityAds Holdings Inc, lower by 7.6%. On the TSX 125 issues rose and 102 fell as a 1.2-to-1 ratio favored advancers. There were 25 new highs and 1 new low, with total volume of 244.4 million shares. The most heavily traded shares by volume were Enbridge Inc, Manulife Financial Corp and Arc Resources Ltd. The TSX s energy group rose 1.19 points, or 1.0%, while the financials sector climbed 0.56 points, or 0.2%.
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
May 07, 2021 07:00 ET | Source: Trillium Therapeutics Inc. Trillium Therapeutics Inc.
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE)
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.
“Coming off an R&D Day last week, we are very excited to have launched a new chapter in Trillium’s evolution,” said Jan Skvarka, Trillium’s President and CEO. “Building on a robust foundation anchored in a demonstrated monotherapy proof of concept of TTI-622 and TTI-621 in multiple lymphoma indications, we have initiated an ambitious Phase 1b/2 program in nine patient settings across hematolog